Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2021

01-03-2021 | Pancreatectomy | Pancreatic Tumors

Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer

Authors: Manabu Kawai, MD, PhD, Seiko Hirono, MD, PhD, Ken-ichi Okada, MD, PhD, Motoki Miyazawa, MD, PhD, Yuji Kitahata, MD, PhD, Ryohei Kobayashi, MD, Masaki Ueno, MD, PhD, Shinya Hayami, MD, PhD, Hiroki Yamaue, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2021

Login to get access

Abstract

Purpose

The prognostic impact of radiographic splenic vessel involvement in pancreatic cancer remains unclear. We evaluate its oncological significance in resectable pancreatic body/tail cancer.

Patients and Methods

We retrospectively review 102 cases of resectable pancreatic cancer and 51 of borderline resectable pancreatic cancer (BRPC) who underwent pancreatectomy for pancreatic body/tail cancer. Resectable pancreatic body/tail cancer was classified into one of three categories based on radiographic splenic vessel involvement.

Results

Among 102 cases of resectable pancreatic cancer, 37 (36.3%), 35 (34.3%), and 30 cases (29.4%) were classified as no splenic vessel involvement (Rnone), splenic vein involvement (RV), and splenic artery involvement (RA), respectively. Disease-free survival (DFS) among patients with Rnone, RV, RA, and BRPC was 58.5, 18.4, 10.8, and 9.2 months, respectively. Patients with RV and RA had significantly poorer DFS than patients with Rnone (P = 0.010, P < 0.001, respectively). Median survival among Rnone, RV, RA, and BRPC was 80.6, 23.4, 15.1, and 21.3 months, respectively. Patients with RV and RA had significantly poorer survival than patients with Rnone (P = 0.001, P < 0.001, respectively) and had short survival similar to that of those with BRPC. Multivariate Cox proportional hazard analysis detected preoperative CA19-9 ≥ 37 IU/L, radiologic splenic vein involvement, radiologic splenic artery involvement, intraoperative bleeding ≥ 500 ml, transfusion, positive washing cytology, and noncompletion of adjuvant therapy as independent prognostic factors.

Conclusions

Radiographic splenic artery involvement is a poor prognostic factor in resectable pancreatic body/tail cancer and may have a role in stratification of treatment strategy.
Literature
1.
2.
Shimada K, Sakamoto Y, Sano T, Kosuge T. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006;139:288–95.CrossRef
3.
Kanda M, Fujii T, Sahin TT, et al. Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. Ann Surg. 2010;251:483–7.CrossRef
4.
Partelli S, Crippa S, Barugola G, et al. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. Ann Surg Oncol. 2011;18:3608–14.CrossRef
5.
Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Onoe S. Prognostic impact of splenic artery invasion for pancreatic cancer of the body and tail. Int J Surg. 2016;35:64–8.CrossRef
6.
Mizumoto, T, Toyama H, Asari S, et al. Pathological and radiological splenic vein involvement are predictors of poor prognosis and early liver metastasis after surgery in patients with pancreatic adenocarcinoma of the body and tail. Ann Surg Oncol. 2018;25:638–46.CrossRef
7.
Hyun JJ, Rose JB, Alseidi AA, et al. Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. J Surg Oncol. 2019;120:262–9.PubMed
8.
Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133:521–7.CrossRef
9.
Hirano S, Kondo S, Hara T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Ann Surg. 2007;246:46–51.CrossRef
10.
Okada K, Kawai M, Tani M, et al. Surgical strategy for patients with pancreatic body/tail carcinoma: who should undergo distal pancreatectomy with en-bloc celiac axis resection? Surgery 2013;153:365–372.CrossRef
11.
James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. TNM classification of malignant tumours. 8th ed. Hoboken: Wiley-Blackwell; 2017.
12.
Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265:565–573.CrossRef
13.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.CrossRef
14.
Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 2017;161:584–91.CrossRef
15.
Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;142:761–768.CrossRef
16.
Hirono S, Kawai M, Okada KI, et al. treatment strategy for borderline resectable pancreatic cancer with radiographic artery involvement. Pancreas 2016;45:1438–1446.CrossRef
17.
Yamaue H, Satoi S, Kanbe T, et al. Phase II clinical study of alternate-day oral therapywithS-1 as first-line chemotherapy for locally-advanced and metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2014;73:97–102.CrossRef
18.
Okada KI, Kawai M, Hirono S, et al. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol. 2016;78:719–26.CrossRef
19.
Okada KI, Hirono S, Kawai M, et al. Phase I study of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Anticancer Res. 2017;37:853–858.CrossRef
20.
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRef
21.
Uesaka K, Boku N, Fukutomi A, et al; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.
22.
Tani M, Kawai M, Terasawa H, et al. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol. 2006;93:485–90.CrossRef
23.
Takahashi H, Akita H, Gotoh K, et al. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence. Surgery. 2015;157:484–95.CrossRef
24.
Yang R, Lu M, Qian X, et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J Cancer Res Clin Oncol. 2014;140: 2077–86.CrossRef
25.
Mitsunaga S, Hasebe T, Kinoshita T, et al. Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol. 2007;31:1636–44.CrossRef
26.
Makino I, Kitagawa H, Ohta T, et al. Nerve plexus invasion in pancreatic cancer: spread patterns on histopathologic and embryological analyses. Pancreas 2008;37:358–65.CrossRef
27.
Shimada K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas 2011;40:464–8.CrossRef
28.
Stopczynski RE, Normolle DP, Hartman DJ, et al. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res. 2014;74:1718–27.CrossRef
29.
Amit M, Na’ara S, Gil Z. Mechanisms of cancer dissemination along nerves. Nat Rev Cancer. 2016;16:399–408.CrossRef
30.
Nagakawa T, Kayahara M, Ohta T, et al. Patterns of neural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol. 1991;10:113–119.PubMed
31.
Fabre JM, Houry S, Manderscheid JC, et al. Surgery for left-sided pancreatic cancer. Br J Surg. 1996;83:1065–1070.CrossRef
32.
Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215–22.CrossRef
33.
Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153–9.CrossRef
34.
Murakami Y, Uemura K, Sudo T, et al. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol. 2017;79:37–47.CrossRef
35.
Eguchi H, Takeda Y, Takahashi H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and s-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26:4498–4505.CrossRef
36.
Reni M, Balzano G, Zanon S, et al. Safty and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol. 2018;3:413–423.CrossRef
37.
de Geus SW, Eskander MF, Bliss LA, et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery 2017;161:592–601.CrossRef
38.
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 2017;35:515–22.CrossRef
39.
Nelson DW, Chang SC, Grunkemeier G, et al. Resectable distal pancreas cancer: time to reconsider the role of upfront surgery. Ann Surg Oncol 2018;25:4012–4019.CrossRef
40.
Crippa S, Cirocchi R, Maisonneuve P, et al. Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. Eur J Surg Oncol 2018;44:24–30.CrossRef
41.
Malleo G, Maggino L, Ferrone CR, et al. Number of examined lymph nodes and nodal status assessment in distal pancreatectomy for body/tail ductal adenocarcinoma. Ann Surg. 2019;270:1138–1146.CrossRef
42.
Asano D, Nara S, Kishi Y, et al. A single-institution validation study of lymph node staging by the AJCC 8th edition for patients with pancreatic head cancer: a proposal to subdivide the N2 category. Ann Surg Oncol. 2019;26:2112–20.
43.
Metadata
Title
Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer
Authors
Manabu Kawai, MD, PhD
Seiko Hirono, MD, PhD
Ken-ichi Okada, MD, PhD
Motoki Miyazawa, MD, PhD
Yuji Kitahata, MD, PhD
Ryohei Kobayashi, MD
Masaki Ueno, MD, PhD
Shinya Hayami, MD, PhD
Hiroki Yamaue, MD, PhD
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08922-8

Other articles of this Issue 3/2021

Annals of Surgical Oncology 3/2021 Go to the issue

ASO Author Reflections

ASO Author Reflections: Every Step Counts: Improved Survival of Retroperitoneal Sarcoma Patients During the Past 15 Years

Pancreatic Tumors

Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer

Breast Oncology

Effect of Intraoperative Imprint Cytology Followed by Frozen Section on Margin Assessment in Breast-Conserving Surgery

ASO Author Reflections

ASO Author Reflections: Sequential Decision Tree Analysis Reveals Pivotal Branch Points in Predicting Implant-Based Reconstruction Failure Outcomes

ASO Author Reflections

ASO Author Reflections: Ultrasound Assessment of the Lymphatic Drainage Area in Melanoma Patients With In-Transit Metastases

Gastrointestinal Oncology

Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study